論文

査読有り 国際誌
2021年7月

An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models.

Oncology reports
  • Tomohiro Tanaka
  • ,
  • Tomokazu Ohishi
  • ,
  • Teizo Asano
  • ,
  • Junko Takei
  • ,
  • Ren Nanamiya
  • ,
  • Hideki Hosono
  • ,
  • Masato Sano
  • ,
  • Hiroyuki Harada
  • ,
  • Manabu Kawada
  • ,
  • Mika K Kaneko
  • ,
  • Yukinari Kato

46
1
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.3892/or.2021.8083

Trophoblast cell surface antigen 2 (TROP2), reported to be overexpressed in several types of cancer, is involved in cell proliferation, invasion, metastasis, and poor prognosis of many types of cancer. Previously, a highly sensitive anti‑TROP2 monoclonal antibody (clone TrMab‑6; mouse IgG2b, κ) was developed using a Cell‑Based Immunization and Screening (CBIS) method. TrMab‑6 was useful for investigations using flow cytometry, western blot, and immunohistochemistry. The aim of the present study was to investigate whether TrMab‑6 possesses in vitro antibody‑dependent cellular cytotoxicity (ADCC) or complement‑dependent cytotoxicity (CDC) activities or in vivo antitumor activities using mouse xenograft models of TROP2‑overexpressed CHO‑K1 (CHO/TROP2) and breast cancer cell lines, including MCF7, MDA‑MB‑231, and MDA‑MB‑468. In vitro experiments revealed that TrMab‑6 strongly induced ADCC and CDC activities against CHO/TROP2 and the three breast cancer cell lines, whereas it did not show those activities against parental CHO‑K1 and MCF7/TROP2‑knockout cells. Furthermore, in vivo experiments on CHO/TROP2 and MCF7 xenografts revealed that TrMab‑6 significantly reduced tumor growth, whereas it did not show antitumor activities against parental CHO‑K1 and MCF7/TROP2‑knockout xenografts. The findings suggest that TrMab‑6 is a promising treatment option for TROP2‑expressing breast cancers.

リンク情報
DOI
https://doi.org/10.3892/or.2021.8083
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34013368
ID情報
  • DOI : 10.3892/or.2021.8083
  • PubMed ID : 34013368

エクスポート
BibTeX RIS